BeiGene Total Depreciation and Amortization - Cash Flow 2014-2024 | ONC
BeiGene annual/quarterly total depreciation and amortization - cash flow history and growth rate from 2014 to 2024. Total depreciation and amortization - cash flow can be defined as the total amount of depreciation and amortization listed on the Cash Flows Statement
- BeiGene total depreciation and amortization - cash flow for the quarter ending September 30, 2024 was $0.122B, a 90.3% increase year-over-year.
- BeiGene total depreciation and amortization - cash flow for the twelve months ending September 30, 2024 was $0.285B, a 47.91% increase year-over-year.
- BeiGene annual total depreciation and amortization - cash flow for 2023 was $0.088B, a 32.28% increase from 2022.
- BeiGene annual total depreciation and amortization - cash flow for 2022 was $0.066B, a 42.67% increase from 2021.
- BeiGene annual total depreciation and amortization - cash flow for 2021 was $0.046B, a 46.14% increase from 2020.
BeiGene Annual Total Depreciation and Amortization - Cash Flow
(Millions of US $) |
| 2023 |
$88 |
| 2022 |
$66 |
| 2021 |
$46 |
| 2020 |
$32 |
| 2019 |
$19 |
| 2018 |
$10 |
| 2017 |
$5 |
| 2016 |
$2 |
| 2015 |
$2 |
| 2014 |
$2 |
| 2013 |
$2 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$17.962B |
$2.459B |
|
BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.
|
